Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan
Authors' conclusion
We demonstrated the incidence and trend of ONJ by antiresorptive agent dose over a 5-year period in Kure after launching the multiprofession study.
Study context
- Population
- Residents of Kure city, Japan, 2016–2020; Osteonecrosis of the jaw (ONJ) cases from a registry launched in 2015
- Participants
- 98 eligible ONJ patients
- Exposure
- Antiresorptive agent use vs no antiresorptive agent use
- Outcome
- ONJ incidence by antiresorptive agent dosage and among people without antiresorptive agents
- Follow-up
- Annual, 2016 to 2020
Methodological detailsclaims database, multiprofession registry, Medication-related ONJ (MRONJ) diagnosed by American Association of Oral and Maxillofacial Surgeons criteria, annual numbers with and without antiresorptive agents from claims database
- Claims database
- Multiprofession registry
- MRONJ diagnosed by American Association of Oral and Maxillofacial Surgeons criteria
- Annual numbers with and without antiresorptive agents from claims database
Main finding
As reported in the abstract
Annual ONJ incidence (per 100,000)
Incidence ratio
23.6
95% CI 13.3–41.8P < 0.001
Low-dose · osteoporosis patients
Incidence ratio
420.6
95% CI 220.8–801.4P < 0.001
High-dose · cancer patients
Observational data: associations, not effects.
Further findings
Trend in MRONJ incidence, 2016–2020
- MRONJ incidence increased from 2016 to 2020, but high-dose MRONJ incidence decreased (nonsignificant)
Original publication
Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int. Published 31 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →